FDA calls for adcomm to discuss Novo Nordisk's filing for weekly insulin

For Novo Nordisk to gain approval in the United States for its groundbreaking Awiqli (insulin icodec), it will have to first pass muster with a panel of experts next month, according (PDF) to a notice in the Federal Register.